Literature DB >> 27292047

POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.

Christopher S King1, Steven D Nathan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27292047     DOI： 10.1016/j.chest.2016.04.034

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  3 in total

1.  3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs.

Authors:  Ranu Surolia; Fu Jun Li; Zheng Wang; Huashi Li; Gang Liu; Yong Zhou; Tracy Luckhardt; Sejong Bae; Rui-Ming Liu; Sunad Rangarajan; Joao de Andrade; Victor J Thannickal; Veena B Antony
Journal:  JCI Insight       Date:  2017-01-26

2.  A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology.

Authors:  Hongfei Liu; Kunyu Du; Dongli Li; Yi Du; Jumei Xi; Ying Xu; Yan Shen; Tao Jiang; Thomas J Webster
Journal:  Int J Nanomedicine       Date:  2018-12-10

3.  Caveolin-1 gene therapy inhibits inflammasome activation to protect from bleomycin-induced pulmonary fibrosis.

Authors:  Xin Lin; Michael Barravecchia; R Matthew Kottmann; Patricia Sime; David A Dean
Journal:  Sci Rep       Date:  2019-12-23       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.